Overview

* Seer Q2 revenue grows 32% yr/yr to $4.1 mln, driven by product sales

* Operating expenses decreased 21% due to lower stock-based compensation

* Net loss narrowed to $19.4 mln from $22.9 mln in prior year

Outlook

* Seer expects 2025 revenue to be $17 mln to $18 mln

* Company anticipates 24% revenue growth for full year 2025

Result Drivers

* PRODUCT SALES - Revenue growth driven by increased sales of Proteograph instruments and consumable kits

* NEW PRODUCT LAUNCHES - Launch of Proteograph ONE assay and SP200 instrument enhanced scalability and efficiency

* COLLABORATION - Partnership with Korea University for a large-scale study utilizing Proteograph ONE assay

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 $4.05

Revenue mln

Q2 EPS -$0.33

Q2 Net -$19.42

Income mln

Q2 Gross 52.0%

Margin

Q2 Gross $2.11

Profit mln

Q2 $22.64

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the office equipment peer group is "buy"

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)